Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 1/20 | 0.52 |
| ▸ | TUBB | P07437 | 1/20 | 0.52 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.52 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.52 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.52 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.52 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.52 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.52 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.52 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.52 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.52 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.52 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.52 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.52 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2527363 | 1.00 | TUBB4A (0.52) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL25307810 | 0.89 | TUBB4A (0.47) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL2527364 | 0.89 | TUBB4A (0.47) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL30674849 | 0.89 | TUBB4A (0.47) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL29450481 | 0.83 | TUBB4A (0.54) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL240027 | 0.83 | ALDH1A1 (0.51) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL29679379 | 0.83 | ALDH1A1 (0.51) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL424747 | 0.83 | TUBB4A (0.54) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL2211699 | 0.82 | TSHR (0.47) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL3051920 | 0.81 | TUBB4A (0.52) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250281424-A1 | SMALL MOLECULE ANTAGONISTS OF PF4 | ZHOU YUHANG (US) | 2025-09-11 | — | — | US | disclosed |
| CN-115703776-B | Plasmin inhibitor, preparation method and application thereof | 赛诺哈勃药业（成都）有限公司 | 2025-06-17 | — | — | CN | disclosed |
| CN-119954801-A | TAU protein targeting compounds and related methods of use | 阿尔维纳斯运营股份有限公司 | 2025-05-09 | — | — | CN | disclosed |
| CN-114867727-B | TAU protein targeting compounds and related methods of use | 阿尔维纳斯运营股份有限公司 | 2025-02-21 | — | — | CN | disclosed |
| US-20240300986-A1 | PLASMIN INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SCINNOHUB PHARMACEUTICAL CO., LTD (CN) | 2024-09-12 | — | — | US | disclosed |
| CN-114245798-B | CGRP antagonist compounds | 奈克斯拉制药英国有限公司 | 2024-08-27 | — | — | CN | disclosed |
| CN-110891951-B | Compounds of formula (I) | 谢菲尔德大学 | 2024-08-20 | — | — | CN | disclosed |
| EP-3628045-B1 | COMPOUNDS | UNIV SHEFFIELD (GB) | 2024-07-03 | — | — | EP | disclosed |
| US-20240124443-A1 | PLASMIN INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | SCINNOHUB PHARMACEUTICAL CO., LTD (CN) | 2024-04-18 | — | — | US | disclosed |
| CN-117545757-A | 5-oxo-pyrido [2,3-d ] pyridazin-6 (5H) -ylacetamides | 詹森药业有限公司 | 2024-02-09 | — | — | CN | disclosed |
| CN-117337288-A | AXL inhibitor compounds | 艾库斯生物科学有限公司 | 2024-01-02 | — | — | CN | disclosed |
| EP-4289850-A1 | PLASMIN INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Scinnohub Pharmaceutical Co., Ltd (CN) | 2023-12-13 | — | — | EP | disclosed |
| EP-4273135-A1 | PLASMIN INHIBITOR, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Scinnohub Pharmaceutical Co., Ltd (CN) | 2023-11-08 | — | — | EP | disclosed |
| WO-2022166845-A1 | PLASMIN INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 赛诺哈勃药业（成都）有限公司 | 2022-08-11 | — | — | WO | disclosed |
| CN-114867727-A | TAU protein targeting compounds and related methods of use | 阿尔维纳斯运营股份有限公司 | 2022-08-05 | — | — | CN | disclosed |
| US-11400081-B2 | Compounds | THE UNIVERSITY OF SHEFFIELD (GB) | 2022-08-02 | — | — | US | disclosed |
| WO-2022143911-A1 | PLASMIN INHIBITOR, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 赛诺哈勃药业（成都）有限公司 | 2022-07-07 | — | — | WO | disclosed |
| EP-3983416-A1 | CGRP ANTAGONIST COMPOUNDS | Heptares Therapeutics Limited (GB) | 2022-04-20 | — | — | EP | disclosed |
| WO-2022073003-A1 | SMALL MOLECULE ANTAGONISTS OF PF4 | NEW YORK BLOOD CENTER, INC (US) | 2022-04-07 | — | — | WO | disclosed |
| CN-114245798-A | CGRP antagonist compounds | 赫普泰雅治疗有限公司 | 2022-03-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250281424-A1 | SMALL MOLECULE ANTAGONISTS OF PF4 | PF4, F12, F2 | TUBB4A 2219/4885TUBB 3468/4885TUBA3C 2788/4885 |
| US-20240124443-A1 | PLASMIN INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | F2, PLG, PLAT | TUBB4A 4055/4885TUBB 3647/4885TUBA3C 3550/4885 |
| US-20240300986-A1 | PLASMIN INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | F2, PLG, PLAT | TUBB4A 3974/4885TUBB 3489/4885TUBA3C 3582/4885 |
| US-11400081-B2 | Compounds | MRGPRX2, MC2R, ADM2 | TUBB4A 2941/4885TUBB 3310/4885TUBA3C 2425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.